Meeting
2016 ASCO Annual Meeting
Icotinib versus vinorelbine/platinum as adjuvant therapy in stage II-IIIA non-small cell lung cancer with EGFR-mutations: A multicenter, randomized, positive-controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501).
Authors
Jianxing He
The First Affiliated Hospital of Guangzhou Medical College, Guangzhou,Guangdong Province, China
Jianxing He , Wenhua Liang , Shidong Xu , Shaofa Xu , Jianying Zhou , Weimin Mao , Qun Wang , Xiuyi Zhi , Fenlai Tan , Lieming Ding , Caicun Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT02448797
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS8570)
DOI
10.1200/JCO.2016.34.15_suppl.TPS8570
Abstract #
TPS8570
Poster Bd #
198a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
First Author: Yuming Zhu
Poster
2021 ASCO Annual Meeting
Different exposure duration of adjuvant icotinib in stage II-IIIA non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): A randomized, open-label phase 2 study.
First Author: Chao Lyu
Poster
2019 ASCO Annual Meeting
The role of EGFR inhibitors as adjuvant therapy for EGFR mutation positive non-small cell lung cancer.
First Author: Peng Xie
Poster
2021 ASCO Annual Meeting
Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR+ NSCLC.
First Author: Dongsheng Yue